Peter Nigrovic
Peter A. Nigrovic, MD is the Prince Turki bin Abdul Aziz al-Saud Professor of Pediatrics at Harvard Medical School and Chief of the Division of Immunology at Boston Children's Hospital, including sections of Allergy, Clinical Immunology, Rheumatology, and Dermatology. He is board certified in both adult and pediatric rheumatology. In 2005 he founded the Center for Adults with Pediatric Rheumatic Illness (CAPRI) at the Brigham and Women's Hospital, the largest provider of transitional rheumatology care in Boston. His laboratory studies basic mechanisms of inflammation with a focus on arthritis and lupus.
Financial relationships
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:BMSTopic:arthritisDate added:11/16/2021
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:BMSTopic:arthritisDate added:11/16/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Miach OrthopaedicsTopic:DSMB chairDate added:11/16/2021Relationship end date:11/10/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:CerecorTopic:arthritisDate added:11/16/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:PfizerTopic:arthritisDate added:11/16/2021
-
Attribution:SelfType of financial relationship:Grant Or ContractIneligible company:PfizerTopic:neutrophil biologyDate added:11/16/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Quench BioTopic:inflammasomeDate added:11/16/2021Relationship end date:06/01/2020
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:SigilonTopic:inflammationDate added:11/16/2021Relationship end date:05/01/2020
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:Exo TherapeuticsTopic:inflammationDate added:11/16/2021
-
Attribution:SelfType of financial relationship:Independent contractorIneligible company:NovartisTopic:arthritisDate added:11/16/2021